Literature DB >> 14968412

Cytology of human ovarian surface epithelial brushings.

Santo V Nicosia1, George D Wilbanks, Beatriz Saunders, James Mayer, Richard J Cardosi, Patricia A Kruk, Jin Cheng, Wenlong Bai, Domenico Coppola, James Fiorica.   

Abstract

BACKGROUND: The human ovarian surface epithelium (HOSE) is the putative source of ovarian epithelial cancer, the most lethal gynecologic malignancy that affects women in the United States. The current study was designed to provide a database of normal HOSE cell features for diagnostic and research applications.
METHODS: HOSE was harvested from 42 women undergoing laparoscopy or laparotomy for benign gynecologic disorders, infertility problems, or pregnancy. Of the 42 women, 12 were postovulatory and 20 were receiving hormonal regimens. Cells were harvested with a sterile brush inserted through a laparoscopic port or with a sterile cell scraper at laparotomy.
RESULTS: Two HOSE populations were identified, ranging in size from 8 to 10 microm and from 15 to 20 microm, respectively. The cells measuring 15-20 microm exhibited slight anisonucleosis, more prominent nucleoli, fine cytoplasmic metachromasia, and an overall reparative or squamoid morphology. Cells were single or arranged in small clusters, sheets, or papillae. They coexpressed cytokeratin and vimentin but did not overexpress p53. Cellularity and proliferation (up to 3.2% +/- 0.8) were higher and papillae more frequent in postovulatory and cyst-bearing ovaries, including polycystic ovaries, suggesting underlying ovarian or hormonal influences. Representative HOSE brushings yielded a mean of 23,133 cells per patient (range, 4250-64,500 cells), equivalent to an estimated 0.58, 0.46, and 0.14 microg of nuclear protein, cell RNA, and nuclear DNA, respectively. Within 7-10 days of explantation, HOSE cells formed confluent monolayers with immunohistochemical and ultrastructural epithelial features.
CONCLUSIONS: The current study defined baseline features of HOSE cells important to pathologists and clinicians evaluating women at risk for ovarian epithelial cancer and to researchers investigating the pathobiology of this aggressive gynecologic malignancy. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 14968412     DOI: 10.1002/cncr.20001

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research.

Authors:  Mark E Sherman; Richard Guido; Nicolas Wentzensen; Hannah P Yang; Phuong L Mai; Mark H Greene
Journal:  Gynecol Oncol       Date:  2012-08-29       Impact factor: 5.482

2.  Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker.

Authors:  Melissa S Derycke; Stefan E Pambuccian; C Blake Gilks; Steve E Kalloger; Abderrezak Ghidouche; Marc Lopez; Robin L Bliss; Melissa A Geller; Peter A Argenta; Katherine M Harrington; Amy P N Skubitz
Journal:  Am J Clin Pathol       Date:  2010-11       Impact factor: 2.493

3.  Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

Authors:  John D Andersen; Kristin Lm Boylan; Ronald Jemmerson; Melissa A Geller; Benjamin Misemer; Katherine M Harrington; Starchild Weivoda; Bruce A Witthuhn; Peter Argenta; Rachel Isaksson Vogel; Amy Pn Skubitz
Journal:  J Ovarian Res       Date:  2010-09-10       Impact factor: 4.234

4.  S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.

Authors:  Melissa S DeRycke; John D Andersen; Katherine M Harrington; Stefan E Pambuccian; Steve E Kalloger; Kristin L M Boylan; Peter A Argenta; Amy P N Skubitz
Journal:  Am J Clin Pathol       Date:  2009-12       Impact factor: 2.493

5.  BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells.

Authors:  Joshua D O'Donnell; Nicole C Johnson; Tracy D Turbeville; Michelle Y Alfonso; Patricia A Kruk
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-07-02       Impact factor: 2.416

6.  Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Authors:  Mark E Sherman; Marion Piedmonte; Phuong L Mai; Olga B Ioffe; Brigitte M Ronnett; Linda Van Le; Iouri Ivanov; Maria C Bell; Stephanie V Blank; Paul DiSilvestro; Chad A Hamilton; Krishnansu S Tewari; Katie Wakeley; Noah D Kauff; S Diane Yamada; Gustavo Rodriguez; Steven J Skates; David S Alberts; Joan L Walker; Lori Minasian; Karen Lu; Mark H Greene
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

7.  Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation.

Authors:  Kristin L M Boylan; Benjamin Misemer; Melissa S De Rycke; John D Andersen; Katherine M Harrington; Steve E Kalloger; C Blake Gilks; Stefan E Pambuccian; Amy P N Skubitz
Journal:  Int J Mol Sci       Date:  2011-02-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.